Berkshire Asset Management LLC PA raised its stake in Medtronic plc. (NYSE:MDT) by 2.7% in the 4th quarter, Holdings Channel reports. The firm owned 87,048 shares of the medical technology company’s stock after buying an additional 2,310 shares during the quarter. Berkshire Asset Management LLC PA’s holdings in Medtronic were worth $7,029,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. Schwab Charles Investment Management Inc. grew its holdings in shares of Medtronic by 4.7% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 5,029,344 shares of the medical technology company’s stock valued at $406,120,000 after acquiring an additional 227,449 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Medtronic by 6.9% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 22,021 shares of the medical technology company’s stock valued at $1,778,000 after acquiring an additional 1,421 shares in the last quarter. First National Trust Co grew its holdings in shares of Medtronic by 12.5% in the fourth quarter. First National Trust Co now owns 39,135 shares of the medical technology company’s stock valued at $3,160,000 after acquiring an additional 4,361 shares in the last quarter. Accredited Investors Inc. grew its holdings in shares of Medtronic by 17.2% in the fourth quarter. Accredited Investors Inc. now owns 5,528 shares of the medical technology company’s stock valued at $446,000 after acquiring an additional 810 shares in the last quarter. Finally, Creative Planning grew its holdings in shares of Medtronic by 3.9% in the fourth quarter. Creative Planning now owns 101,019 shares of the medical technology company’s stock valued at $8,157,000 after acquiring an additional 3,773 shares in the last quarter. 81.75% of the stock is owned by hedge funds and other institutional investors.

In other news, EVP Hooman Hakami sold 26,158 shares of the firm’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $85.00, for a total value of $2,223,430.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Richard Kuntz sold 78,526 shares of the firm’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $86.21, for a total value of $6,769,726.46. Following the completion of the transaction, the vice president now directly owns 149,761 shares of the company’s stock, valued at $12,910,895.81. The disclosure for this sale can be found here. Insiders sold 136,684 shares of company stock valued at $11,582,596 over the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Medtronic plc. (MDT) opened at $86.68 on Friday. Medtronic plc. has a twelve month low of $73.59 and a twelve month high of $89.72. The firm has a market capitalization of $118,110.00, a price-to-earnings ratio of 23.81, a price-to-earnings-growth ratio of 2.37 and a beta of 0.99. The company has a current ratio of 2.40, a quick ratio of 2.05 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.08. Medtronic had a return on equity of 12.63% and a net margin of 16.93%. The business had revenue of $7.05 billion during the quarter, compared to analyst estimates of $7.05 billion. During the same period in the prior year, the company earned $1.12 earnings per share. Medtronic’s revenue was down 4.0% compared to the same quarter last year. equities research analysts predict that Medtronic plc. will post 4.77 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, January 19th. Stockholders of record on Friday, December 29th were issued a $0.46 dividend. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.12%. The ex-dividend date of this dividend was Thursday, December 28th. Medtronic’s payout ratio is currently 50.55%.

Several equities analysts have recently issued reports on the company. Jefferies Group reaffirmed a “buy” rating and issued a $96.00 target price on shares of Medtronic in a report on Thursday, September 28th. SunTrust Banks reaffirmed a “buy” rating and issued a $96.00 target price on shares of Medtronic in a report on Monday, October 2nd. Stifel Nicolaus reduced their target price on Medtronic from $91.00 to $83.00 and set a “hold” rating for the company in a report on Monday, October 9th. Wells Fargo & Co lowered Medtronic from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $93.00 to $83.00 in a report on Monday, October 9th. Finally, Needham & Company LLC reduced their target price on Medtronic from $95.00 to $94.00 and set a “buy” rating for the company in a report on Tuesday, October 10th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and fifteen have issued a buy rating to the company. Medtronic presently has an average rating of “Buy” and a consensus target price of $89.65.

ILLEGAL ACTIVITY WARNING: “Berkshire Asset Management LLC PA Has $7.03 Million Stake in Medtronic plc. (MDT)” was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/berkshire-asset-management-llc-pa-has-7-03-million-stake-in-medtronic-plc-mdt/1814924.html.

Medtronic Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc. (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.